Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Zoetis Inc.

$78.71

+1.45 (+1.88%)

0Pipeline Score NOT_PHARMA
Market Cap
34.09 B
EPS
6.04
P/E Ratio
13.47 $
Value Trade
624.32 M
SEC Financials
Q1 2026
  • Dilution Risk

    5%
  • Revenue

    2.26 B

  • R&D Expenses

    180.00 M

  • Operating CF

    401.00 M


  • Total Assets

    15.15 B

  • Total Liabilities

    11.92 B

  • Equity

    3.23 B

  • D/E Ratio

    12,345

7.85 %
Week
-31.64 %
1 Month
-35.63 %
3 Month
-30.13 %
6 Month
-53.94 %
5 Year
158.16 %
All Time
Cash Data
Profitable
  • Cash Position

    1.94 B

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable
  • SEC Filing

    May 7, 2026
Overview
Volume
17.09 M
52 Week Range
72.38 - 172.23
% held by Insiders
0.57 %
% held by Institutions
100.91 %
Enterprise Value
41.39 B
Total Shares
420.41 M
Short %
3.51 %
Float Shares
383.83 M
Company Description
HQ: 10 SYLVAN WAY, PARSIPPANY, NJ,...
Employees:14,500

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
0
Pipeline Score
-
Pipeline Value
Valuation Signal
0
Drugs Scored
rNPV / MCap
Top 3%
Micro Cap
(rank 879 of 905)
Percentile Rank
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLD
INSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLD
HEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ZTS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZTS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZTS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ZTS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ZTS Institutional Ownership Trends
Current Insider %
5.20%
+0.00%
Current Institutional %
62.40%
+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ZTS
May 21, 2026
ZTSConferences/Events

Zoetis to Participate in Upcoming Investor Conferences

Zoetis is set to participate in several upcoming investor conferences. Details regarding the specific conferences and the content of their presentations have not been disclosed in the article. This participation indicates Zoetis's ongoing engagement with investors and stakeholders in the biopharma sector.

Read more →
ZTS
May 20, 2026
ZTSGeneral

Zoetis Declares Third Quarter 2026 Dividend

Zoetis has announced its third quarter dividend for 2026. The declaration is part of the company's ongoing commitment to return value to its shareholders. Further details about the dividend amount and payment date were not provided in the announcement.

Read more →
ZTS
May 20, 2026
ZTSBackfill

Media Contacts Investor Contacts Jennifer Albano Steve Frank 1-862-399-0810 (o) 1-973-822-7141 (o) jennifer.albano zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (o) 1-973-443-2792 (o) la

Read more →
ZTS
May 7, 2026
ZTSGeneral

Zoetis Announces First Quarter 2026 Results

Zoetis Inc. reported its Q1 2026 financial results, showing a 3% revenue increase to $2.3 billion, with net income at $601 million. The U.S. segment faced challenges, with an 8% revenue decline due to heightened competition and price sensitivity among pet owners. In contrast, the International segment saw a 17% revenue increase, driven by strong demand for companion animal products. The company remains optimistic about its pipeline of potential blockbusters and ongoing innovation efforts.

Read more →
ZTS
May 7, 2026
ZTSBackfill

Zoetis Announces First Quarter 2026 Results Revenue of $2.3 Billion, Growing 3%, and Net Income of $601 Million, or $1.42 per Diluted Share, Flat and Increasing 6%, Respectively, on a Reported Basis Adjusted Net Income o

Read more →
ZTS
Apr 2, 2026
ZTSConferences/Events

Zoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results

Zoetis has announced a webcast and conference call to discuss its financial results for the first quarter of 2026. The event aims to provide insights into the company's performance during this period. Further details regarding the timing and access to the call will likely be shared closer to the date.

Read more →
ZTS
Mar 5, 2026
ZTSConferences/Events

Zoetis to Participate in Upcoming March 2026 Investor Conferences

Zoetis Inc. has announced that Wetteny Joseph, the CFO, will participate in upcoming investor conferences in March 2026. Interested parties can access live audio webcasts of the presentations through the Zoetis investor website, with replays available afterward. This participation highlights Zoetis's commitment to engaging with investors and sharing insights about its operations.

Read more →
ZTS
Mar 2, 2026
ZTSGeneral

Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation

Zoetis Inc. has announced its agreement to acquire Neogen's animal genomics business for $160 million. This acquisition aims to enhance Zoetis' Precision Animal Health portfolio by integrating advanced genomic technologies. The deal is expected to close in the second half of 2026, pending regulatory approvals. The acquisition will bolster Zoetis' commitment to livestock innovation and customer value.

Read more →
ZTS
Feb 24, 2026
ZTSConferences/Events

Zoetis to Participate in the Bank of America Securities 2026 Animal Health Summit

Zoetis Inc. will participate in the Bank of America Securities 2026 Animal Health Summit on February 26, 2026. Wetteny Joseph, the Executive Vice President and CFO, will represent the company during the event. Interested parties can access a live audio webcast and a replay will be available afterward on Zoetis' website.

Read more →
ZTS
Feb 12, 2026
ZTSGeneral

Zoetis Reports Fourth Quarter and Full Year 2025 Results

Zoetis Inc. reported strong financial results for Q4 and full year 2025, with revenues of $2.4 billion and $9.5 billion, respectively. The company highlighted growth in adjusted net income and successful regulatory approvals for new osteoarthritis pain products. Looking ahead, Zoetis provided guidance for 2026 and emphasized its commitment to innovation and market expansion.

Read more →
ZTS
Dec 30, 2025
ZTSConferences/Events

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results

Zoetis Inc. will host a webcast and conference call on February 12, 2026, to discuss its fourth quarter and full year 2025 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and answer questions from analysts. The event will be accessible to the public via the company's investor website.

Read more →
ZTS
Dec 2, 2025
ZTSConferences/Events

Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast

Zoetis Inc. hosted an Innovation Webcast to discuss its R&D leadership and growth opportunities in animal health. CEO Kristin Peck emphasized the company's commitment to innovation and the importance of animals in society. The webcast featured key executives and showcased Zoetis's plans to advance therapies and solutions for animal care.

Read more →
ZTS
Nov 4, 2025
ZTSBackfill

Zoetis Announces Third Quarter 2025 Results Reports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quart

Read more →
ZTS
Aug 5, 2025
ZTSBackfill

Zoetis Announces Second Quarter 2025 Results, Raises Full Year 2025 Outlook Reports Revenue of $2.5 Billion, Growing 4%, and Net Income of $718 Million, or $1.61 per Diluted Share, Increasing 15% and 18%, Respectively, o

Read more →
ZTS
May 6, 2025
ZTSBackfill

Zoetis Announces First Quarter 2025 Results Reports Revenue of $2.2 Billion, Growing 1%, and Net Income of $631 Million, or $1.41 per Diluted Share, Increasing 5% and 8%, Respectively, on a Reported Basis for First Quart

Read more →
ZTS
Feb 13, 2025
ZTSBackfill

Zoetis Reports Fourth Quarter and Full Year 2024 Results Reports Revenue of $2.3 Billion, Growing 5%, and Net Income of $581 Million, or $1.29 per Diluted Share, Increasing 11% and 13%, Respectively, on a Reported Basis

Read more →
ZTS
Feb 6, 2025
ZTSBackfill

Media Contacts Investor Contacts Jennifer Albano Steve Frank 1-973-945-4333 (o) 1-973-822-7141 (o) jennifer.albano zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (o) 1-973-443-2792 (o) la

Read more →
ZTS
Nov 4, 2024
ZTSBackfill

Zoetis Announces Third Quarter 2024 Results Reports Revenue of $2.4 Billion, Growing 11%, and Net Income of $682 Million, or $1.50 per Diluted Share, Increasing 14% and 16%, Respectively, on a Reported Basis for Third Qu

Read more →
ZTS
Oct 10, 2024
ZTSBackfill

Media Contacts Investor Contacts Jennifer Albano Steve Frank 1- 862-399-0810 (o) 1-973-822-7141 (o) jennifer.albano zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (o) 1-973-443-2792 (o) l

Read more →
ZTS
Aug 6, 2024
ZTSBackfill

Zoetis Announces Second Quarter 2024 Results Reports Revenue of $2.4 Billion, Growing 8%, and Net Income of $624 Million, or $1.37 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for Second Qua

Read more →
ZTS
May 22, 2024
ZTSBackfill

Media Contacts Investor Contacts Jenielle Alonso Steve Frank 1-973-945-4333 (o) 1-973-822-7141 (o) jenielle.alonso zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (o) 1-973-443-2792 (o) la

Read more →
ZTS
May 2, 2024
ZTSBackfill

Zoetis Announces First Quarter 2024 Results Reports Revenue of $2.2 Billion, Growing 10%, and Net Income of $599 Million, or $1.31 per Diluted Share, Increasing 9% and 10%, Respectively, on a Reported Basis for First Qua

Read more →
ZTS
Feb 13, 2024
ZTSBackfill

Zoetis Reports Fourth Quarter and Full Year 2023 Results For Fourth Quarter 2023, Zoetis Reports Revenue of $2.2 Billion, Growing 8%, and Net Income of $525 Million, or $1.14 per Diluted Share, Increasing 14% and 15%, Re

Read more →
ZTS
Feb 6, 2024
ZTSBackfill

Media Contacts Investor Contacts Jenielle Alonso Steve Frank 1-973-945-9333 (o) 1-973-822-7141 (o) jenielle.alonso zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (o) 1-973-443-2792 (o) la

Read more →
ZTS
Dec 7, 2023
ZTSBackfill

Media Contacts Investor Contacts Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (o) 1-973-443-2792 (o) laura.pan

Read more →
ZTS
Nov 2, 2023
ZTSBackfill

Zoetis Announces Third Quarter 2023 Results Reports Revenue of $2.2 Billion, Growing 7%, and Net Income of $596 Million, or $1.29 per Diluted Share, Increasing 13% and 14%, Respectively, on a Reported Basis for Third Qua

Read more →
ZTS
Oct 12, 2023
ZTSBackfill

Media Contacts Investor Contacts Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (c) 1-973-443-2792 (o) laura.pan

Read more →
ZTS
Aug 8, 2023
ZTSBackfill

Zoetis Announces Second Quarter 2023 Results Reports Revenue of $2.2 Billion, Growing 6%, and Net Income of $671 Million, or $1.45 per Diluted Share, Increasing 27% and 29%, Respectively, on a Reported Basis for Second Q

Read more →
ZTS
May 11, 2023
ZTSBackfill

Media Contacts Investor Contacts Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price zoetis.com steve.frank zoetis.com Kristen Seely Nick Soonthornchai 1-973-443-2777 (o) 1-973-443-2792 (o) kristen

Read more →
ZTS
May 4, 2023
ZTSBackfill

Zoetis Announces First Quarter 2023 Results Reports Revenue of $2.0 Billion, Growing 1%, and Net Income of $552 Million, or $1.19 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for First Quart

Read more →
ZTS
Feb 14, 2023
ZTSBackfill

Zoetis Reports Fourth Quarter and Full Year 2022 Results For Fourth Quarter 2022, Zoetis Reports Revenue of $2.0 Billion, Growing 4%, and Net Income of $461 Million, or $0.99 per Diluted Share, on a Reported Basis Delive

Read more →
ZTS
Nov 3, 2022
ZTSBackfill

Zoetis Announces Third Quarter 2022 Results Reports Revenue of $2.0 Billion, Growing 1%, and Net Income of $529 Million, or $1.13 per Diluted Share, Decreasing 4% and 3%, Respectively, on a Reported Basis for Third Quart

Read more →
ZTS
Oct 13, 2022
ZTSBackfill

Document Media Contacts Investor Contacts Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price zoetis.com steve.frank zoetis.com Kristen Seely Nick Soonthornchai 1-973-443-2777 (o) 1-973-443-2792 (o

Read more →
ZTS
Aug 4, 2022
ZTSBackfill

Zoetis Announces Second Quarter 2022 Results Reports Revenue of $2.1 Billion, Growing 5%, and Net Income of $529 Million, or $1.12 per Diluted Share, Increasing 3% and 5%, Respectively, on a Reported Basis for Second Qua

Read more →
ZTS
May 5, 2022
ZTSBackfill

Zoetis Announces First Quarter 2022 Results Reports Revenue of $2.0 Billion, Growing 6%, and Net Income of $595 Million, or $1.26 per Diluted Share, Increasing 6% and 8%, Respectively, on a Reported Basis for First Quart

Read more →
ZTS
Feb 15, 2022
ZTSBackfill

Zoetis Reports Fourth Quarter and Full Year 2021 Results For Fourth Quarter 2021, Zoetis Reports Revenue of $2.0 Billion, Growing 9%, and Net Income of $414 Million, or $0.87 per Diluted Share, on a Reported Basis Report

Read more →
ZTS
Nov 4, 2021
ZTSBackfill

Zoetis Announces Third Quarter 2021 Results Reports Revenue of $2.0 Billion, Growing 11%, and Net Income of $552 Million, or $1.16 per Diluted Share, Increasing 15% and 16%, Respectively, on a Reported Basis for Third Qu

Read more →
ZTS
Oct 18, 2021
ZTSBackfill

FOR IMMEDIATE RELEASE Media Contacts: Investor Contacts: Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price@zoetis.com steve.frank@zoetis.com Kristen Seely Keith Gaub 1-973-443-2777 (o) 1-973-822-

Read more →
ZTS
Aug 5, 2021
ZTSBackfill

Zoetis Announces Second Quarter 2021 Results Reports Revenue of $1.9 Billion, Growing 26%, and Net Income of $512 Million, or $1.07 per Diluted Share, Increasing 36% and 35%, Respectively, on a Reported Basis for Second

Read more →
ZTS
May 11, 2021
ZTSBackfill

FOR IMMEDIATE RELEASE Media Contacts : Investor Contacts : Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price@zoetis.com steve.frank@zoetis.com Kristen Seely Keith Gaub 1-973-443-2777 (o) 1-973-82

Read more →
ZTS
May 6, 2021
ZTSBackfill

Zoetis Announces First Quarter 2021 Results Reports Revenue of $1.9 Billion, Growing 22%, and Net Income of $559 Million, or $1.17 per Diluted Share, Increasing 32% and 33%, Respectively, on a Reported Basis for First Qu

Read more →
ZTS
Feb 16, 2021
ZTSBackfill

Zoetis Reports Fourth Quarter and Full Year 2020 Results For Fourth Quarter 2020, Zoetis Reports Revenue of $1.8 Billion, Growing 8%, and Net Income of $359 Million, or $0.75 per Diluted Share, on a Reported Basis Report

Read more →
ZTS
Nov 5, 2020
ZTSBackfill

Zoetis Announces Third Quarter 2020 Results Reports Revenue of $1.8 Billion, Growing 13%, and Net Income of $479 Million, or $1.00 per Diluted Share, Both Increasing 11% on a Reported Basis, for Third Quarter 2020 Report

Read more →
ZTS
Aug 6, 2020
ZTSBackfill

Zoetis Announces Second Quarter 2020 Results Reports Flat Revenue of $1.5 Billion, and Net Income of $377 Million, or $0.79 per Diluted Share, Increasing 2% and 3%, Respectively, on a Reported Basis for Second Quarter 20

Read more →
ZTS
May 6, 2020
ZTSBackfill

Zoetis Announces First Quarter 2020 Results Reports Revenue of $1.5 Billion, Growing 5%, and Net Income of $423 Million, or $0.88 per Diluted Share, Increasing 36% and 35%, Respectively, on a Reported Basis for First Qua

Read more →
ZTS
Feb 13, 2020
ZTSBackfill

Zoetis Reports Fourth Quarter and Full Year 2019 Results For Fourth Quarter 2019, Zoetis Reports Revenue of $1.7 Billion, Growing 7%, and Net Income of $384 Million, or $0.80 per Diluted Share, on a Reported Basis Report

Read more →
ZTS
Feb 11, 2020
ZTSBackfill

FOR IMMEDIATE RELEASE

Read more →
Competitive Position
How ZTS ranks across every disease it competes in
Competitive Position is a premium feature
See how ZTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial